908 Devices

908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. It offers products using mass spectrometry technology, an analytical technique for measuring the mass of charged molecules that is used in chemical analysis laboratories for applications, such as safety and security, food science, biotechnology, clinical diagnostics, and controlling industrial processes. Its products include desktops and handhelds. The company was founded by Kevin J. Knopp, Miller Scott, Steve Araiza, Andrew Bartfay, Michael Jobin, Christopher D. Brown, and Christopher J. Petty in 2012 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

908 Devices reports revenue growth, eyes biopharma sector improvement

908 Devices showed solid financial performance in 2022, with revenue growth and strategic expansions.
While facing challenges like macro headwinds and lower REBEL placements, the company is focused on innovation.
Opportunities lie in biopharma sector improvement, product utilization rates, and unit growth expectations.
Maintaining a strong cash position and disciplined capital deployment are key strengths for future growth.

908 Devices reports revenue growth and strategic partnerships driving innovation

908 Devices delivered solid performance in Q1 2023, marked by revenue growth, strong recurring revenue, and strategic partnerships driving innovation and market expansion.
While facing challenges in operating expenses and gross margins, the company's focus on handheld devices, recurring revenues, and cost management positions it for future success.
With a robust cash position, ongoing product launches, and a diverse sales funnel, 908 Devices is poised to capitalize on opportunities in the biopharma and cell therapy markets.

908 Devices reports revenue growth and strategic focus for growth

908 Devices showcased revenue growth and strong performance in key product segments. While managing expenses prudently and focusing on key markets, the company faces challenges with a net loss and the need for additional handheld unit growth. Opportunities lie in upcoming product launches, government contracts, and pipeline updates.

908 Devices reports Q3 revenue growth, eyes strong 2024 prospects

908 Devices showed solid performance in Q3 2023, driven by growth in handheld devices and strategic collaborations. Despite challenges in the bio-processing space, the company remains optimistic about future growth and product development.
With a strong cash position, no debt, and a focus on returning to high growth rates, 908 Devices is poised for success in 2024. The company's emphasis on process analytical technology tools and expanding market offerings presents promising opportunities for the future.
While facing challenges in revenue expectations and utilization rates, 908 Devices is actively addressing these issues to drive sustainable growth. The company's commitment to innovation and market expansion positions them well for long-term success.

908 Devices reports strong Q4 performance and optimistic outlook for 2024

908 Devices showed revenue growth and improved net loss in Q4 2023, with a positive outlook for 2024.
The company's strong cash position, successful partnerships, and product confidence are key strengths.
Challenges include margin pressures from pricing adjustments and increased spending.
Opportunities lie in revenue growth guidance, customer interest in new products, and market expansion plans.

908 Devices reports solid Q1 performance, eyes growth opportunities

908 Devices had a strong start in Q1 2024, driven by revenue growth and RedWave acquisition.
Challenges include net loss, declining desktop product revenue, and cost management.
Opportunities lie in engagement with cell therapy accounts, revenue synergies, and cash flow improvement.
Strategic fit of RedWave acquisition offers growth potential and cost synergies in the long term.

908 Devices reports solid Q2 earnings, eyes growth through diversification

908 Devices demonstrated strong revenue growth in Q2 2024, driven by robust performance in handheld forensics devices.
While facing challenges in desktop product revenue, the company's focus on recurring revenue and market expansion bodes well for future prospects.
Strategic adjustments and continued emphasis on operational excellence position 908 Devices for sustained success in diverse markets.

908 Devices faces revenue challenges but pursues growth opportunities

908 Devices reported mixed financial performance in Q3 2024, with revenue growth but falling short of expectations, leading to a net loss.
The company is taking steps to optimize operations, identify growth drivers, and drive margin expansion for future success.
Challenges include revenue guidance adjustments, competitive pressures, and financial losses, which require strategic responses.
Opportunities lie in product innovation, strategic partnerships, and effective implementation of sales strategies to drive growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Archer Aviation

Codexis

Ginkgo Bioworks Holdings

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Cathie Wood's ARK Funds Continue to Buy These 5 Stellar ‘Strong Buy' Stocks Trading Under $10

BOSTON--(BUSINESS WIRE)--908 Devices launches the MX908 Beacon, a unique remote area monitoring system that can detect and identify aerosolized and vapor threats.

908 Devices Launches Remote and Continuous Area Monitoring for Aerosol and Vapor Detection

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the second quarter 2023 before market open on Tuesday, August 8, 2023. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.908devic.

908 Devices to Report Second Quarter Financial Results on August 8, 2023

908 Devices Inc. (MASS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

908 Devices Inc. (MASS) Soars 8.5%: Is Further Upside Left in the Stock?

Adaptive Biotechnologies

Genius Sports

KeyCorp

Lucid Group

5 Sizzling ‘Strong Buy' Stocks Under $10, and ARK's Cathie Wood Loves 3 of Them

CareDx

COMPASS Pathways

5 of Cathie Wood's Sizzling ARK Investment Stocks Are Buy Rated and Trading Under $10

Equitrans Midstream

Plug Power

5 ‘Strong Buy' Stocks to Buy Under $10, and Cathie Wood's Ark Owns 2 of Them

BOSTON--(BUSINESS WIRE)--908 Devices Inc (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, is showcasing its ZipChip CE-MS device for rapid characterization of critical product quality attributes for biologics, oligonucleotides, RNAs, and AAVs, with an oral presentation, seminar and 17 posters at the 71st ASMS Conference on Mass Spectrometry and Allied Topics, June 4-8 in Houston. The majority of the scientific presentations are resul.

908 Devices Features its High-Speed, High-Resolution Separations Technology at the 71st ASMS Conference

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming William Blair 43rd Annual Growth Stock Conference. 908 Devices' management is scheduled to present on Wednesday, June 7 at 1:20 p.m. Central Time / 2:20 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.

908 Devices to Participate in the William Blair 43rd Annual Growth Stock Conference

908 Devices, Inc. (NASDAQ:MASS ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Joseph Griffith - CFO & Treasurer Kevin Knopp - Co-Founder, CEO, President & Director Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company Puneet Souda - SVB Securities Stephanie Yan - TD Cowen Jacob Johnson - Stephens Inc. Matthew Larew - William Blair & Company Operator Good morning, ladies and gentlemen, and welcome to the 908 Devices First Quarter 2023 Financial Results Conference Call. [Operator Instructions].

908 Devices, Inc. (MASS) Q1 2023 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended March 31, 2023. “I am pleased to see the strong recurring value that our technology brings to our customers by providing analysis at the point of need,” said Kevin J. Knopp, CEO and Co-founder of 908 Devices. “We are seeing robust demand for our handheld devices while we continue to focus o.

908 Devices Reports First Quarter 2023 Financial Results and Reiterates 2023 Revenue Outlook

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announced the release of a data analysis tool that provides a quick and effortless way to analyze and visualize the wealth of data generated by the REBEL at-line cell culture media analyzer. The tool is provided as a very convenient add-in for the widely used JMP statistical analysis software package. REBEL provides at-line measurement of amin.

908 Devices Launches Data Analysis Visualization Tool for REBEL At-line Cell Culture Media Analyzer

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announced that National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company, has adopted REBEL at-line media analyzers in their process development to inform and optimize cell culture feed strategies and media design. REBEL provides insights into cell metabolism to enable Resilience process engineers to measure spent m.

Resilience Demonstrates Lower Cost of Perfusion Bioreactor Process Using 908 Devices' REBEL At-line Analyzer

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2023 before market open on Tuesday, May 9, 2023. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.908devices.c.

908 Devices to Report First Quarter Financial Results on May 9, 2023

908 Devices Inc. (NASDAQ:MASS ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Kelly Gura – Investor Relations Kevin Knopp – Chief Executive Officer and Co-Founder Joe Griffith – Chief Financial Officer Conference Call Participants Matt Larew – William Blair Puneet Souda – SVB Securities Evan Stampler – Stifel Jacob Johnson – Stephens Operator Good morning, ladies and gentlemen, and welcome to the 908 Devices Fourth Quarter 2022 Financial Results Conference Call. At this time, all lines are in listen-only mode.

908 Devices Inc. (MASS) Q4 2022 Earnings Call Transcript

908 Devices Inc. (MASS) delivered earnings and revenue surprises of -40.91% and 1.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter and full year ended December 31, 2022.

908 Devices Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Revenue Outlook

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming Cowen 43rd Annual Healthcare Conference in Boston, MA. 908 Devices' management is scheduled to host a fireside chat on Wednesday, March 8 at 9:50 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.

908 Devices to Participate in the Cowen 43rd Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the fourth quarter and full year 2022 before market open on Tuesday, March 7, 2023. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

908 Devices to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

908 Devices is a highly rated stock by Wall Street analysts. Seeking Alpha quant ratings state the stock "is at a high risk of performing badly."

908 Devices: The Bull Vs. Bear Tug Of War

BOSTON--( BUSINESS WIRE )--908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced the launch of MAVEN, a device for on-line monitoring and control of glucose and lactate in cell culture and fermentation processes. MAVEN empowers biopharma companies to make timely decisions based on highly sensitive, real-time measurements. Taking measurements as frequently as every two minutes, MAVEN operates without having to manually draw samples out of the bioreactor due to its novel aseptic sampling approach. This improves process understanding, saves operator time and reduces the risk of process contamination--which in turn accelerates development workflows.

908 Devices Unveils New Glucose and Lactate On-Line Device for Bioprocess Monitoring and Control

BOSTON--( BUSINESS WIRE )--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today shared details on the positive impact of the MX908 handheld mass spec device on correctional facility customers across the U.S. in detecting illegal drugs through incoming mail. The MX908 is used to detect and identify illicit drugs, protecting correctional officers, inmates and other bystanders in the process. The device's sensitivity and specificity ensures trace amounts of drugs are detected and false alarms are greatly reduced.

MX908 Device Enables Correctional Facility Personnel to Quickly Identify Illegal Drugs in Incoming Mail

908 Devices Inc. (NASDAQ:MASS ) Q3 2022 Results Conference Call November 14, 2022 8:30 AM ET Company Participants Kelly Gura - IR Kevin Knopp - CEO and Co-Founder Joe Griffith - CFO Conference Call Participants Max Masucci - Cowen Daniel Arias - Stifel Puneet Souda - Leerink Madeline Mollman - William Blair Operator Good day and thank you for standing by. Welcome to the 908 Devices Third Quarter 2022 Financial Results Conference Call.

908 Devices Inc. (MASS) Q3 2022 Earnings Call Transcript

Investors didn't like the medical device maker's update.

Why 908 Devices Stock Is Sinking Today

908 Devices Inc. (MASS) delivered earnings and revenue surprises of 9.09% and 0.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

News for 908 Devices Stock (MASS)